Summary by Futu AI
Eli Lilly and Co reported a significant increase in revenue for both the three and nine months ending September 30, 2024, with a 20% and 27% rise respectively compared to the same periods in 2023. The revenue for the quarter was $9,498.6 million, while the nine-month revenue reached $24,770.7 million. This growth was attributed to increased sales of Mounjaro, Zepbound, and Verzenio, despite a decline in Trulicity sales and the sale of rights for the olanzapine portfolio in 2023. Net income and diluted earnings per share saw a notable turnaround from a loss in the previous year to gains in the current period, with net income reaching $6,180.2 million and earnings per share at $6.83 for the nine months ended September 30, 2024. The improvement in net income and earnings per...Show More